What is the Difference Between CTLA-4 and PD-1?
🆚 Go to Comparative Table 🆚CTLA-4 and PD-1 are two immune checkpoint proteins that play crucial roles in regulating T-cell activity and immune responses. They have distinct functions and operate at different stages of an immune response. Here are the main differences between CTLA-4 and PD-1:
- Expression and location: CTLA-4 is expressed primarily on T cells, while PD-1 is more broadly expressed on activated T cells, B cells, and myeloid cells. CTLA-4 functions during the priming phase of T-cell activation, primarily in lymph nodes. In contrast, PD-1 functions during the effector phase, predominantly within peripheral tissues.
- Ligand distribution: The B7 ligands for CTLA-4 are expressed by professional antigen-presenting cells (APCs), which typically reside in lymph nodes or the spleen. PD-1 ligands, PD-L1 and PD-L2, are more widely expressed, including on leukocytes, nonhematopoietic cells, and in nonlymphoid tissues.
- Role in immune response: CTLA-4 is considered the "leader" of the immune checkpoint and is involved in regulating T-cell activation in lymph nodes/tissues. PD-1, on the other hand, is mainly involved in inhibition of effector T-cell function in peripheral tissues.
- Inhibition strategies: Inhibiting CTLA-4 or PD-1 has different effects on T-cell activity and the immune response. Blocking CTLA-4 primarily affects T-cell proliferation early in an immune response, whereas blocking PD-1 suppresses T cells later in an immune response.
- Adverse event profiles: Inhibiting PD-L1 rather than PD-1 may result in a slightly different toxicity profile, although clinical data are currently limited. Treatment-related grade 3-4 adverse events were reported in 4% to 13% of patients receiving PD-L1 inhibitors.
In summary, CTLA-4 and PD-1 have distinct roles, timing, and locations in immune regulation, and their inhibition leads to different effects on T-cell activity and immune responses.
Comparative Table: CTLA-4 vs PD-1
CTLA-4 and PD-1 are both immune checkpoints that play crucial roles in regulating T-cell activity. Here is a table summarizing the differences between them:
Feature | CTLA-4 | PD-1 |
---|---|---|
Expression | Primarily on T cells | More broadly expressed on activated T cells, B cells, and myeloid cells |
Timing | Regulates T-cell proliferation early in an immune response, primarily in lymph nodes | Suppresses T cells later in an immune response, predominantly within peripheral tissues |
Ligands | B7 ligands (CD80 and CD86) expressed by professional antigen-presenting cells (APCs), typically residing in lymph nodes or spleen | PD-L1 and PD-L2 ligands more widely expressed, including on leukocytes, nonhematopoietic cells, and nonlymphoid tissues |
Function | Confined to T cells | Functions during the effector phase, predominantly within peripheral tissues |
Inhibitory Receptor | CTLA-4 is an inhibitory receptor on T cells that controls peripheral tolerance and the development of autoimmunity | Regulates T-cell activation through binding to its ligands |
Tumor-infiltrating Lymphocytes (TILs) | CTLA-4 expression is associated with an increased amount of TILs | PD-L1 expression is associated with an increased amount of TILs and poorer prognosis |
Therapeutic Implications | Blockade of CTLA-4 or PD-1 may have different effects on T-cell reactivity against tumors based on their distinct modes of action | Inhibiting PD-L1 rather than PD-1 may result in different clinical outcomes |
Despite having similar negative effects on T-cell activity, CTLA-4 and PD-1 have distinct differences in their timing, anatomic locations, signaling mechanisms, and expression.
- CAR-T vs TCR-T
- Immunotherapy vs Targeted Therapy
- CD4 Cells vs CD8 Cells
- T Helper vs T Cytotoxic Cells
- T Cells vs B Cells
- Positive vs Negative Selection of T Cells
- B Cell Receptor vs T Cell Receptor
- B Cell vs T Cell Lymphoma
- Antibodies vs T Cells
- T Lymphocytes vs B Lymphocytes
- Immunotherapy vs Chemotherapy
- Gene Therapy vs Immunotherapy
- Paclitaxel vs Docetaxel
- B Cell vs T Cell Leukemia
- NK Cells vs NKT Cells
- Chemotherapy vs Targeted Therapy
- Lymphokines vs Cytokines
- Cytokines vs Interleukins
- HLA vs MHC